• Alias: IMC-A12, CIX
    • A fully human IgG1/λ monoclonal antibody directed at the IGF-IR
    • Has a dual action of inhibiting the binding of IGF-1 and IGF-2 ligands to the IGF-1R and inducing the rapid internalization of the receptor
    • Currently under investigation in phase 1/2 clinical trials in breast cancer, rhabdomyosarcoma, Ewing sarcoma, NSCL, pancreatic, adrenocortical carcinoma, metastatic prostate cancer, and HCC
    • Phase 1/2 dose: 6 to 10 mg/kg IV Q 1 to 2 weeks
    • Half-life: 148 to 209 hours
    • Common side effects: Hyperglycemia, rash, pruritis, fatigue, nephrotoxicity
    (Higano et al., 2007)
    Other topics in Targeted and Immunotherapy Agents